Cost-Effectiveness of Intravascular Imaging-Guided Complex PCI: Prespecified Analysis of RENOVATE-COMPLEX-PCI Trial
David Hong,Jin Lee,Hankil Lee,Juhee Cho,Eliseo Guallar,Ki Hong Choi,Seung Hun Lee,Doosup Shin,Jong-Young Lee,Seung-Jae Lee,Sang Yeub Lee,Sang Min Kim,Kyeong Ho Yun,Jae Young Cho,Chan Joon Kim,Hyo-Suk Ahn,Chang-Wook Nam,Hyuck-Jun Yoon,Yong Hwan Park,Wang Soo Lee,Taek Kyu Park,Jeong Hoon Yang,Seung-Hyuk Choi,Hyeon-Cheol Gwon,Young Bin Song,Joo-Yong Hahn,Danbee Kang,Joo Myung Lee,the RENOVATE-COMPLEX-PCI Investigators
DOI: https://doi.org/10.1161/circoutcomes.123.010230
2024-03-15
Circulation Cardiovascular Quality and Outcomes
Abstract:Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. Background:Although clinical benefits of intravascular imaging-guided percutaneous coronary intervention (PCI) in patients with complex coronary artery lesions have been observed in previous trials, the cost-effectiveness of this strategy is uncertain.Methods:RENOVATE-COMPLEX-PCI (Randomized Controlled Trial of Intravascular Imaging Guidance vs Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) was conducted in Korea between May 2018 and May 2021. This prespecified cost-effectiveness substudy was conducted using Markov model that simulated 3 states: (1) post-PCI, (2) spontaneous myocardial infarction, and (3) death. A simulated cohort was derived from the intention-to-treat population, and input parameters were extracted from either the trial data or previous publications. Cost-effectiveness was evaluated using time horizon of 3 years (within trial) and lifetime. The primary outcome was incremental cost-effectiveness ratio (ICER), an indicator of incremental cost on additional quality-adjusted life years (QALYs) gained, in intravascular imaging-guided PCI compared with angiography-guided PCI. The current analysis was performed using the Korean health care sector perspective with reporting the results in US dollar (1200 Korean Won, ₩=1 dollar, 35 000 per QALY gained.Results:A total of 1639 patients were included in the trial. During 3-year follow-up, medical costs ( 7236; incremental cost, 57 040 per QALY gained within trial data. Conversely, lifetime simulation showed total cumulative medical cost was reversed between the 2 groups ( 49 519; incremental cost, −$9063) with consistently higher QALY (8.24 versus 7.89; incremental QALY, 0.910) in intravascular imaging-guided PCI than angiography-guided PCI, resulting in a dominant incremental cost-effectiveness ratio. Consistently, 70% of probabilistic iterations showed cost-effectiveness of intravascular imaging-guided PCI in probabilistic sensitivity analysis.Conclusions:The current cost-effectiveness analysis suggests that imaging-guided PCI is more cost-effective than angiography-guided PCI by reducing medical cost and increasing quality-of-life in complex coronary artery lesions in long-term follow-up.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT03381872.
cardiac & cardiovascular systems